Company intelligence / Profile preview
Traverse Biotech
- Ownership
- Private
- Development stage
- Preclinical
Overview
Traverse Biotech is developing next-generation immunotherapies based on clinically validated platforms. Its lead programs are in preclinical stages and focus on novel targets such as ROR2 for T cell engagement in cancer and an oral innate immune stimulator for immunological diseases. The company has received SBIR grants from the NIH/NIAID and National Cancer Institute to support its research efforts[5][6].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Bispecific antibodiesChemical drugs (including innate immune stimulators)
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Traverse Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Traverse Biotech.